Soligenix - רווח למניה אחת ב-12 החודשים האחרונים SNGX

Soligenix, Inc. (SNGX) is actively developing its R&D portfolio of orphan drugs against biotreats, which impacts the annual EPS dynamics over a rolling year. The value of 79.80 characterizes this level, confirming the resilience of the model. Stability is ensured by production at GMP facilities in Europe and the US, while government defense orders amid geopolitical tensions guarantee demand for the drugs.

Year-over-year (YoY) EPS growth (TTM) reflects the percentage change in net income per share over the last twelve months, determining the scaling rate of the business's real income. For Soligenix, Inc. (SNGX), the rolling annual EPS YoY trend on GURU.Markets demonstrates the effectiveness of monetizing niche drugs, where the transition to mass production following certification directly confirms capital stability.